A Literature Review to Assess Methods for Handling Missing Data within the Health Economic Evaluation of Clinical Trials
Author(s)
Garcia Sanchez JJ1, Darlington O2, Boyce R2, Ouwens M3, McEwan P4, Jackson D1
1AstraZeneca, Cambridge, UK, 2Health Economics and Outcomes Research Ltd, Cardiff, UK, 3AstraZeneca, Mölndal, O, Sweden, 4HEOR Ltd, Cardiff, Great Britain
Presentation Documents
OBJECTIVES Data missingness is a common issue in economic evaluations and can lead to substantial bias if not accounted for. Despite this, there is limited guidance on how to address missing data in economic evaluations, and methods are not commonly reported. The objective of this study was to conduct a literature review to identify published literature describing methods to handle missing data in economic evaluations of clinical trials. METHODS A targeted literature review designed according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) checklist was undertaken to identify publications describing methods for handling missing data in health economic evaluations. Electronic databases (Medline and Medline In-Process) were searched from inception to October 2020. Full texts were reviewed to determine study eligibility based on predefined criteria, and data from eligible studies were extracted and reported methods for handling missing data were summarised. RESULTS The review identified 44 publications meeting the eligibility criteria for the review. The most common methods identified to address missing data were multiple imputation (MI) and complete-case analysis (CCA), used in 27 and 14 studies, respectively. MI-MICE (MI with chained equations) was the most common approach when using MI, and CCA was typically compared against more robust methods in sensitivity analysis. Inverse probability weighting (IPW) was used in four studies, however, was found to be outperformed by MI methods. When data are missing at random (MAR), MI and IPW is more precise than CCA, however, the approaches produce similar results when data are missing completely at random. CONCLUSIONS Robust handling of missing data is essential with chosen methods having the potential to directly impact the conclusions made. MI or IPW should be used where data are MAR and compared to results under an assumption of missing not at random, to evaluate the effect of differing assumptions on cost-effectiveness conclusions.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSC307
Topic
Economic Evaluation, Methodological & Statistical Research
Topic Subcategory
Missing Data, Trial-Based Economic Evaluation
Disease
Multiple Diseases, No Specific Disease